Figure 3 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Huang Y-J., Rieder J., Tan KV., Tenditnaya A., Vojnovic B., Gorpas D., Quante M., Vallis KA.
In vivo and ex vivo fluorescence imaging of EMI-137 in the dual xenograft model: A,In vivo fluorescence imaging 3 hours p.i. of EMI-137 showed a strong signal in the OE33 xenograft (right flank, white circle) but not in the FLO-1 xenograft (left flank, gray circle). B, Uptake of EMI-137 in OE33 tumors is effectively but not completely suppressed by coinjecting a 10-fold molar excess of unlabeled EMI-137 as a competitive blocking agent. C, Representative ex vivo tumor and organ panel of the dual xenograft model 3 hours p.i. of EMI-137 showing high uptake in OE33 tumor and kidney. D,Ex vivo tumor and organ panel taken from mice that received EMI-137 plus unlabeled EMI-137 coinjection as a blocking agent. E, Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137. F, Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137 plus a 10-fold molar excess of unlabeled EMI-137 showed more than 50% reduction of fluorescence in OE33 xenograft compared with E. n = 3 mice per group. ****, P < 0.0001. Avg, average; Max, maximum; Min, minimum; ns, not significant.